Device type · CGJ
Radioimmunoassay, Follicle-Stimulating Hormone
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
CGJ
Clinical Chemistry
Device class
Class I
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
5
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Radioimmunoassay, Follicle-Stimulating Hormone
- Product code
- CGJ
- Device class
- Class I
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1300
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for CGJ
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
5
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
5
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 1 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 2 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 1 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 1 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 1 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 1 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 1 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Low Test Results4
- Non Reproducible Results4
- High Test Results3
- Incorrect Measurement2
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions5
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- DiagnosUS One Step FSH Menopausal Test (Strip) REF 210-07Open, Classified
Z-0060-2024 · Started May 22, 2023 · Posted by FDA Oct 23, 2023
Reason given: Universal Meditech Inc. was violatively distributing PrestiBio" Breastmilk Alcohol Test Strip, DiagnosUS SARS-CoV-2 Antibody (IgG/IgM) Test, HealthyWiser KetoFast" Ketone Test Strips and PrestiBio" Ketone Test Strips without marketing authorization. UMI is also recall their tests because they are going out of business...
Cause as FDA categorized it: Other
- VITROS Immunodiagnostic Products FSH Reagent Pack- IVD 1931922Open, Classified
Ortho-Clinical Diagnostics, Inc
Z-1112-2022 · Started Mar 25, 2022
Reason given: Falsely high or delayed patient and QC results may occur due to low end imprecision. VITROS Immunodiagnostic Products FSH, LH and Prol Reagents Low End Imprecision. Low-level quality control (QC) and patient samples at the low end of the Measuring (Reportable) Range when using VITROS FSH, LH and Prol Reagent....
Cause as FDA categorized it: Device Design
- VIDAS FSH, REF 30407-01Open, Classified
Z-0434-2022 · Started Sep 22, 2021
Reason given: bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.
Cause as FDA categorized it: Nonconforming Material/Component
Ortho Clinical Diagnostics Inc
Z-0059-2019 · Started Jul 12, 2018
Reason given: The recalling firm determined that biased results may occur for specific VITROS Immunodiagnostic Products (MicroWell Assays) at biotin concentrations which are lower than indicated in the current Instructions For Use (IFU). Patients who are taking biotin supplements could potentially have biased sample results for...
Cause as FDA categorized it: Device Design
Z-2331-2018 · Started Apr 9, 2018 · Posted by FDA Jun 29, 2018
Reason given: Invalid calibration with low calibrator S1 while using the product.
Cause as FDA categorized it: Under Investigation by firm
Z-2086-2018 · Started Mar 5, 2018
Reason given: Asfotase Alfa (Strensiq) interferes with certain Tosoh assays which potentially causes falsely increased or falsely decreased immunoassay test results, depending upon the assay.
Cause as FDA categorized it: Device Design
PerkinElmer Health Sciences, Inc.
Z-0779-2017 · Started Nov 16, 2016 · Posted by FDA Dec 16, 2016
Reason given: A DELFIA hFSH kit lot failed real time stability testing. The real time stability data demonstrated a decrease in hFSH concentrations between -4.8% to -11.3% for control sera. The -11.3% bias was observed at an hFSH target concentration of 101 IU/L. The change observed in the serum samples within the range 1.76 67.0...
Cause as FDA categorized it: Other
Applied Medical Resources Corp
Z-0644-2013 · Started Nov 5, 2012 · Posted by FDA Jan 7, 2013
Reason given: Applied Medical is conducting a voluntary recall on a specific lot number of its 12x150mm Kii shielded bladed access systems. This is due to a potential for the blade to remain exposed after shield deployment. Further use of any affected product should cease immediately. The affected model number is CTB71, and the...
Cause as FDA categorized it: Nonconforming Material/Component
Showing the 8 newest of 9 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.